Integer Supports Respicardia's Commercialization in the Central Sleep Apnea Market through Two New Agreements

Globe Newswire 14-Jan-2019 4:05 PM

PLANO, Texas and MINNETONKA, Minn., Jan. 14, 2019 (GLOBE NEWSWIRE) -- Integer, a leading medical device outsource (MDO) manufacturer, today announced it has entered into a new development agreement and a new supply agreement with Respicardia, Inc., a medical technology company dedicated to developing innovative therapies that address unmet needs in respiratory and cardiovascular disease. Under the agreements, Integer will be Respicardia's development partner and majority supplier of the remede® implantable pulse generator (IPG) and related products for seven years, the first 5 ½ years as an exclusive supplier.

"We're honored to continue supporting Respicardia in bringing their therapy to market," said Tony Gonzalez, president of Integer's Cardiac Rhythm Management and Neuromodulation product line. "We supported their initial system development as they worked through their clinical studies, so it's exciting to see their transition to commercialization. These agreements highlight Integer's breadth of capabilities to support customers with design, development and manufacturing of custom IPG systems. Our end-to-end expertise will help Respicardia ensure the utmost quality and reliability of their products."

"In product innovation, quality, and uncompromising clinical performance, Integer-manufactured devices are second-to-none," said Peter Sommerness, President and CEO of Respicardia. "Integer is recognized as an innovative company that shares our vision to improve patient quality of life and overall health. Respicardia sought a partner with the ability to scale the production to meet the market needs of our unique therapies."

Respicardia's remede® System is a transvenous neurostimulation device that treats moderate to severe central sleep apnea in adult patients. Central Sleep Apnea (CSA) is a serious breathing disorder that disrupts the normal breathing pattern during sleep and negatively affects quality of life and overall cardiovascular health. CSA results from the brain's failure to send appropriate signals to the respiratory muscles to stimulate breathing.

About Integer

Integer (NYSE:ITGR) is one of the largest medical device outsource (MDO) manufacturers in the world serving the cardiac, neuromodulation, vascular, portable medical, advanced surgical and orthopedics markets. The company provides innovative, high-quality medical technologies that enhance the lives of patients worldwide. In addition, it develops batteries for high-end niche applications in energy, military, and environmental markets. The company's brands include Greatbatch™ Medical, Lake Region Medical™ and Electrochem. Additional information is available at

About Respicardia

Respicardia is a leader in innovative technologies that address the unmet needs in respiratory and cardiovascular disease with safe and effective therapies. Founded in 2006 and headquartered near Minneapolis, Minn., Respicardia is dedicated to improving patient outcomes, quality of life and overall cardiovascular health via novel transvenous neurostimulation therapies. Learn more at


Integer Investor Relations
Tony Borowicz

Integer Media Relations
Kelly Butler

Respicardia Media Relations
Collin Anderson

Image for Press Release 749020

integer logo.jpg

Image for Press Release 749020